High-dose therapy followed by autologous hematopoietic stem-cell infusion for patients with multiple myeloma.
Jack W. Singer(NorthShore University HealthSystem), CD Buckner(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Taner Demirer(Fred Hutch Cancer Center), J Klarnet(Fred Hutch Cancer Center), Thomas R. Chauncey(City Of Hope National Medical Center), Scott D. Rowley(Johns Hopkins Hospital), Richard T. Maziarz(Oregon Health & Science University), Rainer Storb(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), K Lilleby(University of Washington), R A Clift(Fred Hutch Cancer Center), Leona Holmberg(University of Washington), Peter A. McSweeney(Mesoblast (United States)), K Schiffman(University of Washington), A Fefer(University of Washington), T Barnett(Fred Hutch Cancer Center), C H Weaver(Fred Hutch Cancer Center), F R Appelbaum(City Of Hope National Medical Center), David G. Maloney(Fred Hutch Cancer Center)
Cited by 108
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
Chronic graft-versus-host syndrome in man
|The American Journal of Medicine|1980|2.4k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
HLA-Haploidentical Bone Marrow Transplantation for Hematologic Malignancies Using Nonmyeloablative Conditioning and High-Dose, Posttransplantation Cyclophosphamide
|Biology of Blood and Marrow Transplantation|2008|1.9k
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2020|1.9k